Company news from the 01/16/07 news brief

Share this article:
Genizon BioSciences announced a license and collaboration agreement with Pfizer for diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis. Genizon retains therapeutic rights. Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with diseases. Pfizer will also purchase an equity stake in Genizon subject to certain closing conditions. Financial terms were not disclosed. Redi-Direct Marketing has acquired New York-based Dialog Group, including the firm’s Healthcare Dialog division, a developer of relationship marketing and communication programs for the pharmaceutical industry. Financial terms of the deal were not disclosed. CMPMedica has acquired MediReach Healthcare Communications, a Shanghai, China, consultancy providing medical and pharmaceutical marketing services to multinational pharmaceutical companies across China, for an initial payment of $1.1 million and as much as $2.75 million contingent on future performance.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.